Mirum Pharmaceuticals financials
$87.54−0.48%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 |
|---|---|---|---|---|---|---|---|
| Revenue | $521.3M | $336.9M | $186.4M | $77.1M | $19.1M | $0.00 | — |
| Gross profit | $421.1M | $255.2M | $139.3M | $64.7M | $17.2M | $0.00 | — |
| Gross margin | 80.8% | 75.8% | 74.8% | 83.9% | 90.1% | — | — |
| Operating income | -$22.1M | -$87.6M | -$109.2M | -$131.2M | -$173.4M | -$104.3M | -$54.7M |
| Net income | -$23.4M | -$87.9M | -$163.4M | -$135.7M | -$84.0M | -$103.3M | -$52.6M |
| Net margin | −4.5% | −26.1% | −87.7% | −176.0% | −438.9% | — | — |
| Diluted EPS | $-0.47 | $-1.85 | $-4.00 | $-4.02 | $-2.77 | $-4.09 | $-4.58 |
| EBITDA | $2.1M | -$64.0M | -$98.3M | -$128.0M | -$172.8M | -$103.7M | -$54.4M |
| Operating cash flow | $55.8M | $10.3M | -$70.9M | -$120.1M | -$132.8M | -$89.1M | -$39.4M |
| Free cash flow | $54.9M | $9.3M | -$71.1M | -$120.4M | -$132.8M | -$89.3M | -$39.6M |
| Diluted shares | 50.2M | 47.5M | 40.9M | 34.0M | 30.3M | 25.3M | 11.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $296.7M | $222.5M | $286.3M | $28.0M | $31.3M | $142.1M |
| Short-term investments | $86.6M | $57.8M | $0.00 | $123.7M | $125.2M | $89.7M |
| Total debt | $309.8M | $308.1M | $306.4M | $0.00 | $0.00 | $0.00 |
| Total assets | $842.8M | $670.8M | $646.6M | $352.9M | $294.7M | $240.9M |
| Total liabilities | $528.1M | $445.1M | $398.0M | $210.9M | $174.4M | $68.8M |
| Shareholders' equity | $314.7M | $225.6M | $248.7M | $142.0M | $120.2M | $172.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology